rv1162
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2013 (NCT01970618)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- p38 MAP kinase alpha/betaINHIBITOR
p38 MAP kinase alpha/beta inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rv1162
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04759807 | Phase 1 | Jan 4, 2021 | Medicines Evaluation Unit Ltd, Pulmatrix Inc. |
| NCT01970618 | Phase 1 | Oct 1, 2013 | RespiVert, Sponsor GmbH |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medicines Evaluation Unit Ltd | For profit | 1 | 0 | 1 | 2021 |
| Pulmatrix Inc. | For profit | 1 | 1 | 1 | 2021 |
| RespiVert | For profit | 1 | 1 | 1 | 2013 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1